摘要
目的结合临床实践经验,探讨成人咳嗽变异型哮喘患者采用孟鲁司特钠联合异丙托溴铵治疗的临床效果。方法选取2020年12月至2022年5月该院收治的98例成人咳嗽变异型哮喘患者作为研究对象,随机分为联合治疗组和孟鲁司特钠组,每组各49例。孟鲁司特钠组采用孟鲁司特钠治疗,联合治疗组采用孟鲁司特钠联合异丙托溴铵治疗,两组均持续治疗3个月。比较两组患者临床疗效;比较两组患者治疗前后炎症因子水平、肺功能指标水平、哮喘症状评分(ACT评分)和慢性阻塞性肺疾病症状评分(CAT评分);观察两组患者不良反应发生情况。结果联合治疗组患者治疗总有效率为91.84%,明显高于孟鲁司特钠组的77.55%,差异有统计学意义(χ^(2)=6.098,P=0.047)。两组患者治疗后超敏C反应蛋白、肿瘤坏死因子和白细胞介素-13水平均低于治疗前,且联合治疗组患者治疗后均低于孟鲁司特钠组,差异均有统计学意义(P<0.05)。两组患者治疗前ACT评分和CAT评分比较,差异均无统计学意义(P>0.05);联合治疗组患者治疗后ACT评分高于孟鲁司特钠组,CAT评分低于孟鲁司特钠组,差异均有统计学意义(P<0.05)。联合治疗组患者治疗后第1秒用力呼气容积、肺活量、最大通气量均高于孟鲁司特钠组,差异均有统计学意义(P<0.05)。联合治疗组患者不良反应发生率为6.12%,明显低于孟鲁司特钠组的20.41%,差异有统计学意义(χ^(2)=4.346,P=0.037)。结论孟鲁司特钠联合异丙托溴铵治疗成人咳嗽变异型哮喘临床效果明显,可减轻患者炎症反应,提高肺功能,改善临床症状,降低不良反应发生率,值得临床推广应用。
Objective To investigate the clinical effect of montelukast sodium combined with ipratropium bromide in the treatment of adult patients with cough variant asthma.Methods A total of 98 adult patients with cough variant asthma admitted to the hospital from December 2020 to May 2022 were selected as the research objects,and were randomly divided into combined treatment group and montelukast sodium group,with 49 cases in each group.The montelukast sodium group was treated with montelukast sodium,and the combined treatment group was treated with montelukast sodium combined with ipratropium bromide.Both groups were treated for 3 months.The clinical efficacy was compared between the 2 groups.The levels of inflammatory factors and pulmonary function indexes,asthma symptom score(ACT score)and chronic obstructive pulmonary disease symptom score(CAT score)were compared between the 2 groups before and after treatment.The adverse reactions of the 2 groups were observed.Results The total effective rate of combined treatment group was 91.84%,which was significantly higher than 77.55%of montelukast sodium group,and the difference was statistically significant(χ^(2)=6.098,P=0.047).The levels of high-sensitivity C-reactive protein,tumor necrosis factor and interleukin-13 in the 2 groups after treatment were lower than those before treatment,and the combined treatment group were lower than those in montelukast sodium group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in ACT score and CAT score between the 2 groups before treatment(P>0.05).After treatment,the ACT score of combined treatment group was higher than that of montelukast sodium group,and the CAT score was lower than that of montelukast sodium group,and the differences were statistically significant(P<0.05).After treatment,the forced expiratory volume in one second,vital capacity and maximum ventilation volume of combined treatment group were higher than those of montelukast sodium group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in combined treatment group patients was 6.12%,which was significantly lower than 20.41%in montelukast sodium group,and the difference was statistically significant(χ^(2)=4.346,P=0.037).Conclusion The clinical effect of montelukast sodium combined with ipratropium bromide in the treatment of adult cough variant asthma is obvious,which can reduce the inflammatory reaction,improve lung function,improve clinical symptoms,and reduce the incidence of adverse reactions.It is worthy of clinical application.
作者
张冰姿
ZHANG Bingzi(Department of Gastroenterology and Respiratory Medicine,The First Hospital of Tongxu,Kaifeng,Henan 475400,China)
出处
《检验医学与临床》
CAS
2023年第20期3041-3044,共4页
Laboratory Medicine and Clinic
关键词
孟鲁司特钠
异丙托溴铵
成人咳嗽变异型哮喘
临床效果
血清炎症因子
montelukast sodium
ipratropium bromide
adult cough variant asthma
clinical effect
serum inflammatory factor